Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE) - Concepedia

Concepedia

Publication | Open Access

Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE)

DOI Full Paper Access

88

Citations

15

References

2018

Year

Peter Nash, Kamal Ohson, Jessica A. Walsh, Nikolay Delev, Dianne Nguyen, Lichen Teng, Juan J. Gómez‐Reino, Jacob Aelion

Annals of the Rheumatic Diseases

Abstract

NCT01925768; Results.

References

	Year	Citations
Classification criteria for psoriatic arthritis: Development of new criteria from a large international study William J. Taylor, Dafna D. Gladman, Philip Helliwell, Arthritis & Rheumatism	2006	3.6K
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis Laura C. Coates, Arthur Kavanaugh, Philip J. Mease, Arthritis & Rheumatology	2016	899
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1) Kim Papp, Kristian Reich, Craig L. Leonardi, Journal of the American Academy of Dermatology Autoimmune DiseaseMedicinePhase IiiClinical TrialsPlaque Psoriasis	2015	649
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2) C. Paul, Jennifer Clay Cather, Melinda Gooderham, British Journal of Dermatology	2015	464
Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor Arthur Kavanaugh, Philip J. Mease, Juan J. Gómez‐Reino, Annals of the Rheumatic Diseases	2014	435
Measuring clinical enthesitis in psoriatic arthritis: Assessment of existing measures and development of an instrument specific to psoriatic arthritis Paul Healy, Philip Helliwell Arthritis Care & Research	2008	432
Apremilast mechanism of action and application to psoriasis and psoriatic arthritis Peter Schäfer Biochemical Pharmacology InflammationRheumatologyAutoimmune DiseaseMedicineApremilast Mechanism	2012	425
Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis Robert E. Kalb, David Fiorentino, Mark Lebwohl, JAMA Dermatology	2015	364
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3) Christopher J Edwards, Francisco J. Blanco, Jeffrey Crowley, Annals of the Rheumatic Diseases	2016	275
A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial Maurizio Cutolo, Gary E. Myerson, Roy Fleischmann, The Journal of Rheumatology	2016	206

Page 1